Lorbriqua 25 mg Tablet belongs to the group of medicines that inhibit an enzyme called anaplastic lymphoma kinase (ALK). It is used to treat adults with advanced stages of lung cancer called non-small cell lung cancer (NSCLC). Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the lung tissues. There are several types of non-small cell lung cancer. Smoking is the major risk factor for non-small cell lung cancer.

Lorbriqua 25 mg Tablet contains the active substance Lorlatinib, a medicine used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK. Lorbriqua 25 mg Tablet is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase.

Always use this medicine as your doctor has told you or per the package leaflet. You must keep to your doctor's instructions to get the maximum benefit. In some cases, you may experience common side effects such as diarrhoea, constipation, joint pain, weight gain, headache, rash, and muscle pain. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.

Consult your doctor before taking Lorbriqua 25 mg Tablet if you are pregnant or breastfeeding. Lorbriqua 25 mg Tablet may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Lorbriqua 25 mg Tablet as it could lead to increased dizziness. Lorbriqua 25 mg Tablet is not recommended for children below 18 years as safety and effectiveness have not been established. Lorbriqua 25 mg Tablet is listed as pregnancy category D. Because Lorbriqua 25 mg Tablet can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Lorbriqua 25 mg Tablet . Consult your doctor if you are breastfeeding; your doctor will decide whether Lorbriqua 25 mg Tablet can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects. Lorbriqua 25 mg Tablet may affect male fertility. Talk to your doctor about fertility preservation before taking Lorbriqua 25 mg Tablet .

Lorbriqua 25 mg Tablet contains the active substance Lorlatinib, a medicine used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). Lorbriqua 25 mg Tablet is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase. It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK.

Consult your doctor before taking Lorbriqua 25 mg Tablet if you are pregnant or breastfeeding. Lorbriqua 25 mg Tablet may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Lorbriqua 25 mg Tablet as it could lead to increased dizziness. Lorbriqua 25 mg Tablet is not recommended for children below 18 years as safety and effectiveness have not been established. Lorbriqua 25 mg Tablet is listed as pregnancy category D. Because Lorbriqua 25 mg Tablet can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Lorbriqua 25 mg Tablet . Consult your doctor if you are breastfeeding; your doctor will decide whether the Lorbriqua 25 mg Tablet can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects. Lorbriqua 25 mg Tablet may affect male fertility. Talk to your doctor about fertility preservation before taking Lorbriqua 25 mg Tablet .